Prehospital transdermal glyceryl trinitrate for ultra-acute ischaemic stroke: data from the RIGHT-2 randomised sham-controlled ambulance trial
Open Access
- 8 June 2023
- journal article
- research article
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (1) , 38-49
Abstract
Background The effect of transdermal glyceryl trinitrate (GTN, a nitrovasodilator) on clinical outcome when administered before hospital admission in suspected stroke patients is unclear. Here, we assess the safety and efficacy of GTN in the prespecified subgroup of patients who had an ischaemic stroke within the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2). Methods RIGHT-2 was an ambulance-based multicentre sham-controlled blinded-endpoint study with patients randomised within 4 hours of onset. The primary outcome was a shift in scores on the modified Rankin scale (mRS) at day 90. Secondary outcomes included death; a global analysis (Wei-Lachin test) containing Barthel Index, EuroQol-5D, mRS, telephone interview for cognitive status-modified and Zung depression scale; and neuroimaging-determined ‘brain frailty’ markers. Data were reported as n (%), mean (SD), median [IQR], adjusted common OR (acOR), mean difference or Mann-Whitney difference (MWD) with 95% CI. Results 597 of 1149 (52%) patients had a final diagnosis of ischaemic stroke; age 75 (12) years, premorbid mRS>2 107 (18%), Glasgow Coma Scale 14 (2) and time from onset to randomisation 67 [45, 108] min. Neuroimaging ‘brain frailty’ was common: median score 2 [2, 3] (range 0–3). At day 90, GTN did not influence the primary outcome (acOR for increased disability 1.15, 95% CI 0.85 to 1.54), death or global analysis (MWD 0.00, 95% CI −0.10 to 0.09). In subgroup analyses, there were non-significant interactions suggesting GTN may be associated with more death and dependency in participants randomised within 1 hour of symptom onset and in those with more severe stroke. Conclusions In patients who had an ischaemic stroke, ultra-acute administration of transdermal GTN in the ambulance did not improve clinical outcomes in a population with more clinical and radiological frailty than seen in previous in-hospital trials.Keywords
Funding Information
- British Heart Foundation (CS/14/4/30972)
- National Institute for Health and Care Research (Health and Care Research Scholarship, Senior Investigator)
- Stroke Association (SA L-SMP 18\1000)
- UK Dementia Research Institute
This publication has 27 references indexed in Scilit:
- Applications of the Wei-Lachin Multivariate One-Sided Test for Multiple Outcomes on Possibly Different ScalesPLOS ONE, 2014
- Effects of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic StrokeJAMA, 2014
- Feasibility of an Ambulance-Based Stroke Trial, and Safety of Glyceryl Trinitrate in Ultra-Acute StrokeStroke, 2013
- The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trialThe Lancet, 2011
- Improving Modified Rankin Scale Assessment With a Simplified QuestionnaireStroke, 2010
- Is Low-Heat Shock Protein 70 a Primary or a Secondary Event in the Development of Atherosclerosis?Hypertension, 2004
- High Blood Pressure in Acute Stroke and Subsequent OutcomeHypertension, 2004
- Plasma nitric oxide (nitrate/nitrite) levels in acute stroke and their relationship with severity and outcomeJournal of Stroke and Cerebrovascular Diseases, 2003
- Progressive Right Frontotemporal Degeneration: Clinical, Neuropsychological and SPECT CharacteristicsDementia and Geriatric Cognitive Disorders, 1993
- Low dose blockade in acute stroke ("BEST" trial): an evaluationBMJ, 1988